Table 1.
Ref. | Recruited period | Sample size (T/C) | HCC characteristics | First therapy | Adjuvant therapy | Outcomes |
Li et al[6], 2016 | 2009-2013 | 12/24 | With portal vein thrombus | Hepatic resection | Sorafenib (200-800 mg/d) | TTP, P = 0.041 OS, P = 0.01 |
Bruix et al[7], 2015 | 2008-2010 | 556/558 | Early stage HCC | Hepatic resection or ablation | Sorafenib (400 mg) twice a day | RFS, P = 0.26 OS, P = 0.48 |
Lencioni et al[8], 2016 | - | 154/153 | Intermediate stage multinodular HCC | TACE with doxorubicin-eluting beads | Sorafenib (400 mg) twice a day | TTP, P = 0.07 OS, P = 0.29 |
Kudo et al[9], 2011 | 2006-2009 | 229/227 | Unresectable HCC who responded to TACE | Conventional TACE | Sorafenib (400 mg) twice a day | TTP, P = 0.25 OS, P = 0.79 |
C: Control group; HCC: Hepatocellular carcinoma; OS: Overall survival; RFS: Recurrence-free survival; T: Adjuvant treated group; TACE: Transarterial chemoembolization; TTP: Time-to-tumor progression.